Using mobile phones to fight Alzheimer’s disease

8 Aug 2019

Researchers study how radiofrequency electromagnetic fields could be used in Alzheimer’s disease therapy.

Future treatments for age-related dementia could involve mobile phone frequency electromagnetic fields, researchers at Nazarbayev University and the National Laboratory Astana investigate.

Using mobile phones to fight Alzheimer’s disease

The scientists are studying how radiofrequency electromagnetic fields could be used in Alzheimer’s disease therapy, selecting a frequency of 918 MHz because it’s commonly used in mobile phones.

Alzheimer’s disease, the most common form of age-related dementia, is usually characterised by loss of memory and dramatic changes in character and behaviour, eventually leading to an inability to carry out normal daily life activities. The cause of the disease is the accumulation of the toxic beta-amyloid peptide in brain tissues, which leads to oxidative stress, neuroinflammation, mitochondrial dysfunction, and ultimately – the death of nerve cells.

The study provides insight into what happens when an electromagnetic field of 918 MHz frequency suppresses oxidative stress triggered by beta-amyloid.

Researcher Andrey Tsoy says: “Building on the work of scientists from the USA, who conducted experiments with the same parameters in a 6-month period, we used human and rat cultures – model cells – and shorter exposure periods of 60 minutes. The results of our studies, obtained by irradiation of cells with an electromagnetic field frequency of 918 MHz in a period of up to 24 hours, confirmed the ability of the electromagnetic field to suppress oxidative stress, which indicates the possible therapeutic effect.

“Thus, irradiation with an electromagnetic field frequency of 918 MHz can probably be used in the treatment of Alzheimer’s disease patients.”

Nazarbayev University’s scientists plan to continue research in this direction and confirm whether these methods can be implemented in the fight against the devastating disease.

Read More

Related news

FDA Approves rfxcel for Verification Router Service (VRS) Pilot

FDA Approves rfxcel for Verification Router Service (VRS) Pilot

15 Aug 2019

rfxcel, the global leader in supply chain compliance and serialization solutions, has been approved by the U.S. Food and Drug Administration (FDA) to conduct a pilot to extend the testing of the Verification Router Service (VRS) for saleable returns.

Read more 
rfxcel Awarded ISO 9001:2015 Certification

rfxcel Awarded ISO 9001:2015 Certification

14 Aug 2019

rfxcel, the leader in track and trace solutions for global supply chains announced that it is now ISO 9001:2015 certified for Quality Management Systems.

Read more 
How real-world data can revolutionise drug development

How real-world data can revolutionise drug development

9 Aug 2019

Utilising the current data environment and its data pools for the benefit of advancing research.

Read more 
Automation-compatible prepared culture media plate technology

Automation-compatible prepared culture media plate technology

6 Aug 2019

Thermo Fisher Scientific's SmartPlate format brings together Oxoid and Remel prepared culture media with a durable, universal plate design, helping customers to deliver accurate results across both automated and manual methods.

Read more 
Researchers develop 3D printed ingestible pill

Researchers develop 3D printed ingestible pill

4 Aug 2019

Represents the first non-invasive diagnostic tool capable of providing a profile of microbiome populations throughout the entire GI tract.

Read more 
Needle free: Erase wrinkles without injection

Needle free: Erase wrinkles without injection

15 Jul 2019

Meet REVOLUTION BEYOND INNOVATION at Cphi Worldwide 2019, Booth No. 42C06

Read more 
Eisai collaborates with University of Dundee on cancer drug discovery

Eisai collaborates with University of Dundee on cancer drug discovery

10 Jul 2019

It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

Read more 
Fresh data on protein interactions in Alzheimer’s disease

Fresh data on protein interactions in Alzheimer’s disease

2 Jul 2019

Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Read more 
Cyclolab Ltd strengthens its position in the market

Cyclolab Ltd strengthens its position in the market

1 Jul 2019

Cyclolab Ltd. is an R&D and cGMP manufacturing company focusing on all aspects of cyclodextrin science, manufacturing and applications for cyclodextrin, Dexolve, Sugammadex, formulation development, custom synthesis, Niemann Pick C.

Read more 
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more